WAT WATERS CORP /DE/
Laboratory Analytical Instruments · NYSE · SEC CIK 1000697 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY7.0%
TTM net income YoY0.8%
TTM EPS YoY0.5%
Revenue 3-yr CAGR2.1%
Net income 3-yr CAGR-3.2%
Margins
Gross margin59.3%
Operating margin25.4%
Net margin20.3%
FCF margin17.1%
EBITDA margin28.1%
Returns
ROE29.3%
ROA13.3%
ROIC (approx.)22.6%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets49.5%
Debt / equity0.37x
Current ratio1.73x
Interest coverage11.54x
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio-0.2%
Payout ratio—
Capex / revenue3.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.17B | $2.96B |
| Cost of revenue | $1.29B | $1.20B |
| Gross profit | $1.88B | $1.76B |
| R&D expense | $195.71M | $183.03M |
| SG&A expense | $830.37M | $690.15M |
| Operating income | $802.59M | $826.35M |
| Interest expense | $69.55M | $89.68M |
| Pretax income | $754.88M | $754.87M |
| Income tax | $112.25M | $117.03M |
| Net income | $642.63M | $637.83M |
| EBITDA | $890.73M | $913.37M |
| EPS (basic) | 10.80 | 10.75 |
| EPS (diluted) | 10.76 | 10.71 |
| Weighted avg. shares (diluted) | 59.71M | 59.55M |
| Banking | ||
| Net interest income | -$47.71M | -$71.48M |
| Balance sheet | ||
| Cash & equivalents | $588.00M | $325.00M |
| Short-term investments | — | $934,000 |
| Receivables | $829.00M | $733.37M |
| Inventory | $572.00M | $477.26M |
| Current assets | $2.15B | $1.67B |
| PP&E, net | $642.00M | $651.20M |
| Goodwill | $1.34B | $1.30B |
| Intangibles | $558.00M | $567.91M |
| Total assets | $5.08B | $4.55B |
| Current liabilities | $1.24B | $789.76M |
| Long-term debt | $947.00M | $1.63B |
| Total debt | $947.00M | $1.63B |
| Total liabilities | $2.52B | $2.73B |
| Shareholders' equity | $2.56B | $1.83B |
| Net debt | $359.00M | $1.30B |
| Shares outstanding | 59.55M | 59.39M |
| Cash flow statement | ||
| Operating cash flow | $652.55M | $762.12M |
| Capital expenditure | $112.75M | $142.48M |
| Free cash flow | $539.81M | $619.64M |
| Investing cash flow | -$152.25M | -$143.09M |
| Financing cash flow | -$237.21M | -$696.67M |
| Depreciation & amortization | $88.14M | $87.02M |
| Stock-based compensation | $54.13M | $44.71M |
| Share buybacks | $14.67M | $13.54M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.